Related Experiment Video
Updated: Jun 18, 2025

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
Published on: April 6, 2022
Biologic therapy for ulcerative colitis associated with immune thrombocytopenia
Manabu Nagayama1,2, Yohei Funayama1, Osamu Taniguchi1
1Division of Gastroenterology, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Biologics like ustekinumab and adalimumab effectively treat refractory ulcerative colitis (UC) and immune thrombocytopenia (ITP). These treatments induce remission in colitis and improve platelet counts, potentially preventing surgery.
Area of Science:
- Gastroenterology
- Immunology
- Hematology
Background:
- Ulcerative colitis (UC) is a chronic inflammatory bowel disease.
- Extraintestinal manifestations, such as immune thrombocytopenia (ITP), can occur in UC patients.
- Refractory UC poses significant treatment challenges.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...

